Entrada Therapeutics, Inc. (TRDA)
6.56
-0.55
(-7.74%)
USD |
NASDAQ |
Sep 10, 12:28
Entrada Therapeutics Debt to Equity Ratio : 0.208 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.208 |
| March 31, 2026 | 0.1837 |
| December 31, 2025 | 0.1664 |
| September 30, 2025 | 0.1538 |
| June 30, 2025 | 0.1442 |
| March 31, 2025 | 0.1366 |
| December 31, 2024 | 0.1381 |
| September 30, 2024 | 0.1451 |
| June 30, 2024 | 0.1499 |
| March 31, 2024 | 0.2466 |
| December 31, 2023 | 0.2815 |
| September 30, 2023 | 0.28 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.353 |
| March 31, 2023 | 0.0707 |
| December 31, 2022 | 0.122 |
| September 30, 2022 | 0.1198 |
| June 30, 2022 | 0.1168 |
| March 31, 2022 | 0.1148 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 298.88M |
| Total Liabilities (Quarterly) | 65.47M |
| Shareholders Equity (Quarterly) | 233.41M |
| Current Ratio | 10.89 |
| Net Debt Paydown Yield | 0.59% |